替莫唑胺在恶性胶质瘤综合治疗中的临床疗效观察  

Effects of temozolomide on patients with malignant gliomas

作　　者：段宝奇[1] 李海林[2] 樊练[1] 朱海峰[2] 

机构地区：[1]江苏省中医院神经外科 [2]江苏省人民医院神经外科,江苏南京210029

出　　处：《中国生化药物杂志》2009年第3期194-196,共3页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的探讨替莫唑胺(TMZ)在恶性胶质瘤综合治疗中的有效性和安全性。方法对63例恶性脑胶质瘤患者资料进行回顾性分析,其中19例接受手术+TMZ化疗的综合性治疗;21例接受手术+外放疗的综合性治疗;23例接受手术+外放疗+TMZ化疗的综合性治疗。观察各组生存率、无进展生存时间、总生存时间和TMZ药物安全性。结果手术+外放疗+TMZ化疗组的年生存率明显高于其他组。3组的平均无进展生存时间为依次为(41.5±3.95),(45.72±3.74),(56.33±3.36)周;平均总生存时间依次为(47.65±3.97),(56.33±3.74),(62.27±3.19)周。有2个病人使用TMZ出现白细胞减少,经减量处理后好转。结论替莫唑胺结合手术和外放疗是恶性胶质瘤的有效治疗方法,病人可良好耐受。Purpose To study the efficacy and security of temozolomide（TMZ） on patients with malignant gliomas. Methods A retrospective study was made on 63 malignant glioma patients. 23 cases underwent surgery plus radiotherapy and chemotherapy （ therapy group ） , 2 1 cases underwent surgery plus radiotherapy, and 19 cases underwent surgery plus chemotherapy （control group）. The median survival time, survival rate and safety were evaluated. Results The median survival time and survival rate were signifiantly different. Two pa- tients experienced leucopenia and released with dose reduction treatment. Conclusion Temozolomide plus surgery and radiotherapy obtained better effects than other methods and was well tolerated

关 键 词：替莫唑胺 恶性胶质瘤 综合治疗 疗效 

分 类 号：R979.1[医药卫生—药品]